muraglitazar has been researched along with Cardiovascular Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Califf, RM; Demets, D; George, JT; Gerstein, HC; Granger, C; Green, JB; Hobbs, T; Holman, RR; Lawson, FC; Leiter, LA; McGuire, DK; McMurray, J; Pagidipati, NJ; Pfeffer, MA; Reusch, J; Riesmeyer, JS; Roe, MT; Rosenberg, Y; Sharma, A; Temple, R; Wiviott, S | 1 |
| Drosatos, K; Kalliora, C | 1 |
| Amoroso, R; Maccallini, C; Mollica, A | 1 |
| Nissen, SE; Topol, EJ; Wolski, K | 1 |
| Brophy, JM | 1 |
| Doux, JD; Lee, PY; Yun, AJ | 1 |
| Finkelstein, JB | 1 |
| Beckey, C; Parra, D; Thomas, T | 1 |
| Najman, DM | 1 |
| Doggrell, SA | 1 |
2 review(s) available for muraglitazar and Cardiovascular Diseases
| Article | Year |
|---|---|
The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARĪ± and PPARĪ³ Activation.
Topics: Alkanesulfonates; Animals; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Signal Transduction; Thiophenes | 2020 |
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.
Topics: Animals; Cardiovascular Diseases; Glycine; Humans; Nitric Oxide Synthase Type III; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2017 |
8 other study(ies) available for muraglitazar and Cardiovascular Diseases
| Article | Year |
|---|---|
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucose; Glycated Hemoglobin; Glycine; Government Regulation; Humans; Hypoglycemic Agents; Oxazoles; Phenylbutazone; Practice Guidelines as Topic; Risk; Rosiglitazone; Tolbutamide; United States; United States Food and Drug Administration | 2020 |
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Selling safety--lessons from muraglitazar.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk; United States; United States Food and Drug Administration | 2005 |
Paradoxical inflammation revisited: muraglitazar and cardiovascular risk.
Topics: Cardiovascular Diseases; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Risk | 2006 |
Drug safety system needs overhaul, experts say.
Topics: Cardiovascular Diseases; Conflict of Interest; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Glycine; Heart; Humans; Journalism, Medical; Oxazoles; Peroxisome Proliferator-Activated Receptors; Publication Bias; United States; United States Food and Drug Administration | 2006 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones | 2006 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Oxazoles; PPAR alpha; PPAR gamma | 2006 |
Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Middle Aged; Oxazoles; Randomized Controlled Trials as Topic; Research Design; Weight Gain | 2006 |